Kenvue position on acetaminophen (Tylenol®) and autism claims
We believe independent, sound science shows Tylenol® is safe and taking acetaminophen does not cause autism
Media contacts
Working members of the media, please contact the Kenvue media relations team with inquiries.
- Please put ON DEADLINE in the subject of the email and be as specific as possible with your request.
- Requests received after business hours will be responded to as soon as possible.
$15.5 bn+
Net sales for 2024
As the world’s largest pure-play consumer health company by revenue.
135+
Year history
Across our brands — redefining what care really means.
~1.2bn
Global consumers
The number of lives we touch around the world.
Latest news
Find out what’s new in our world of care.
Kenvue unveils foundational consumer trends report A New View of Care, highlighting the transformative power of personal care routines
- Study underscores shift toward viewing personal care as a tool for overall well-being as well as appearance
- Trusted vs. go-to sources for personal care advice are not always the same
- Consumers plan to invest more time in personal care routines
- Trusted vs. go-to sources for personal care advice are not always the same
- Consumers plan to invest more time in personal care routines
Kenvue reports second quarter 2025 results
• Net sales (4.0)%; organic sales1 (4.2)%
• Diluted EPS was $0.22; adjusted diluted EPS1 was $0.29
• Continues to advance ongoing review of strategic alternatives, while taking actions to accelerate profitable growth under the new executive team
• Revises outlook for FY’25
• Diluted EPS was $0.22; adjusted diluted EPS1 was $0.29
• Continues to advance ongoing review of strategic alternatives, while taking actions to accelerate profitable growth under the new executive team
• Revises outlook for FY’25
Kenvue announces CEO transition and actions to unlock shareholder value
• Appoints current Kenvue Director and proven CPG and technology company leader, Kirk Perry, as Interim CEO, effective immediately
• Announces ongoing review of strategic alternatives
• Reports select preliminary second quarter 2025 financial results
• Announces ongoing review of strategic alternatives
• Reports select preliminary second quarter 2025 financial results
Kenvue releases second annual Healthy Lives Mission report
- Company reports reduction of operational emissions by 37%, expanded use of renewable electricity to 72% and launch of multiple packaging innovations across portfolio
Kenvue announces leadership transition in Asia Pacific region
- Anindya Dasgupta, 30-year consumer products industry veteran to join Kenvue, appointed Group President, Asia Pacific, effective July 14, 2025
Tylenol® expands expertise to proactive joint care with launch into the supplement category
From relief to routine: Proactive Support from the Makers of Tylenol® delivers clinically backed ingredients that provide effective, drug-free joint support.†
The National Women’s Soccer League and Tylenol® announce multi-year partnership
Tylenol®, the #1 doctor-recommended pain relief brand, becomes official pain reliever of NWSL
Our commitments
At Kenvue, our impact is made through moments of care—the daily care we offer consumers through our portfolio of iconic brands and the actions we take to protect our environment. Our approach to sustainability is designed to effectively govern and manage impacts while also enabling us to identify opportunities that accelerate innovation, profitable growth and drive business value for all our stakeholders. We call it our Healthy Lives Mission. It’s how we show everyday care in action.
37%
reduction in Emissionsas of 2024
~72%
of Kenvue operations run on renewable electricityas of 2024
21.4%
reduction in use of virgin plasticas of 2024
~56M+
donated in product and monetary aid worldwideas of 2024